Search for European Projects

9 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Universal Flu Vaccine (UNIVACFLU)

Start date: Nov 1, 2013, End date: Oct 31, 2017,

Currently licensed influenza vaccines promote an effective antibody response, but only against influenza virus strains that antigenically match the vaccine composition. Little protection is induced by these vaccines against antigenically drifted strains such as those emerging from an avian or swine reservoir. Hence there is a great need to develop broadly cross-reactive flu-vaccines.The aim is to ...
Read Project

 8

 FINISHED 
ObjectivesWe have discovered that early-onset inflammatory bowel disease (IBD) can be caused by mutations in IL10 or its receptor. This project aims to identify further patients suffering from IL10/IL10 receptor deficiency and to clarify the pathomechanism causing the severe phenotype of the patients.DesignThe project will investigate patients with early-onset IBD. Patients will have blood samples ...
Read Project

 1

 FINISHED 

HEPATIC MICROFLUIDIC BIOREACTOR (HEMIBIO)

Start date: Jan 1, 2011, End date: Dec 31, 2015,

The goal of HeMiBio is to develop a hepatic microfluidic bioreactor from human iPSC-derived hepatocytes, hepatic sinusoidal endothelial cells (HSEC) and stellate cells (HSC), suitable for inclusion in a repeated dose toxicity testing strategy of pharmaceuticals/cosmetic ingredients. The successful creation of such a liver-device requires (a) homotypic and heterotypic interactions between the three ...
Read Project

 13

 FINISHED 
MicroRNAs (miRNAs) negatively regulate gene expression by promoting mRNA degradation and inhibiting mRNA translation. Recent studies have uncovered key roles of miRNAs as mediators of cardiovascular development and disease, but much remains to be learned about their mechanisms of action and regulation. Dr. Olson's lab has described a family of muscle-specific miRNAs, referred to as MyomiRs, which ...
Read Project

 1

 FINISHED 

Development of novel antiviral drugs against Influenza (FLUCURE)

Start date: Oct 1, 2010, End date: Sep 30, 2014,

"Influenza viruses cause a highly contagious respiratory disease in both humans and animals. Typically, influenza spreads worldwide in seasonal epidemics resulting in an estimated 3 to 5 million cases of severe illness and 250,000 to 500,000 deaths annually. In addition to these seasonal epidemics there have been several pandemics since the early 1900’s, where highly virulent strains emerged, the ...
Read Project

 11

 FINISHED 
First-line immunomodulatory treatments such as beta-interferons (IFN-alpha/beta) for multiple sclerosis are available to reduce the rate of relapses and disease activity. However, in addition to its therapeutic effect, systemic IFN-beta treatment causes severe neuropsychiatric complications in humans, including depression and cognitive impairments. These side effects are common and can limit the t ...
Read Project

 1

 FINISHED 

Persisting Transgenesis (PERSIST)

Start date: Jan 1, 2009, End date: Jun 30, 2013,

"For many disabling or fatal diseases, there is pre-clinical or clinical evidence of the potential therapeutic efficacy of gene therapy and, yet, the limitations of current gene transfer technologies have prevented success or even caused serious adverse events leading to termination of trials. PERSIST will explore the use of highly innovative gene-modifying and delivery technologies and capitalize ...
Read Project

 29

 FINISHED 
Mental health care represents over a third of the cost of health care to all EU nations. However little is being done to develop effective systems for Prevention of the onset of the illnesses or to provide easier Diagnosis with a view to better determine the effects of treatment.OPTIMI will change this by developing tools to perform Prediction through early identification of the onset of an illnes ...
Read Project

 13

 FINISHED 
We present an interdisciplinary project which aims to evaluate the neurobiological correlates of emotion processing in primary insomnia. The dimensional approach of emotions (e.g. Bradley, 2000) suggests that they can be described by referring to two dimensions: arousal and valence. In insomnia, while the role of arousal has been widely investigated, few studies have considered the valence. This s ...
Read Project

 1